Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 5/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009427 | 0.90 | CCNK (1.00) | CCNKCDK12NUDT1CCNE1CDK2 | |
| SCHEMBL20839635 | 0.90 | CCNK (1.00) | CCNKCDK12NUDT1CCNE1CDK2 | |
| SCHEMBL20849889 | 0.83 | CCNK (0.79) | CCNKCDK12NUDT1CCNE1CDK2 | |
| SCHEMBL20839751 | 0.81 | CCNK (1.00) | CCNKCDK12JAK1 | |
| SCHEMBL30574749 | 0.81 | CCNK (0.75) | CCNKCDK12NUDT1CCNE1CDK2 | |
| SCHEMBL99693 | 0.81 | CCNK (0.67) | CCNKCDK12NUDT1JAK1PRKCI | |
| SCHEMBL29541183 | 0.81 | CCNK (0.67) | CCNKCDK12NUDT1JAK1PRKCI | |
| SCHEMBL20849913 | 0.79 | CCNK (1.00) | CCNKCDK12NUDT1CCNE1CDK2 | |
| SCHEMBL719570 | 0.75 | CCNK (0.71) | CCNKCDK12CCNE1CDK2KDR | |
| SCHEMBL25351686 | 0.74 | CCNK (0.64) | CCNKCDK12CCNE1CDK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| WO-2019058132-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | CDK1, CDK11A, CDK12 | CCNK 18/4885CDK12 3/4885NUDT1 1300/4885 |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | CCNK 18/4885CDK12 3/4885NUDT1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.